Skip to main content

Table 4 Response Evaluation for Each Dose Cohort

From: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Dose Cohort Response in evaluable patient (n = 37) Disease control (%)
  CR PR SD PD CR+PR+SD
250 mg 0 1 1 1 2 (66.7)
500 mg 0 2 4 3 6 (66.7)
750 mg 0 2 9 0 11 (100)
850 mg 0 2 8 1 10 (90.9)
1000 mg 0 0 2 1 2 (66.7)
Total 0 7 24 6 31 (83.8)
  1. Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.